Nasdaq · Healthcare

Sonoma Pharmaceuticals, Inc. (SNOA)

As-reported financials and recent SEC filings for Sonoma Pharmaceuticals, Inc., latest fiscal period FY2026. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$19.5M

Net income

$-3.2M

Net margin

-16.3%

Diluted EPS

$-1.89

ROE

-102.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2026	FY2025	FY2024	FY2023	FY2022
Revenue	$19.5M	$14.3M	$12.7M	$13.3M	$12.6M
Gross profit	$7.4M	$5.5M	$4.7M	$4.5M	$4.0M
Operating income	$-2.5M	$-3.7M	$-4.7M	$-4.6M	$-5.9M
Net income	$-3.2M	$-3.5M	$-4.8M	$-5.2M	$-5.1M
Diluted EPS	$-1.89	$-2.79	$-3.54	$-3.55	$-0.00

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

DEFA14A2026-06-24

8-K2026-06-18

424B52026-06-18

10-K2026-06-16

DEF 14A2026-05-05

8-K2026-04-30

424B42026-04-27

PRE 14A2026-04-27

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on SNOA

Search Sonoma Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.